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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on the safety of Schizochytrium sp. oil as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. Schizochytrium sp. is a single-cell microalga.
The strain FCC-3204, used by the applicant (Fermentalg), belongs to the species Schizochytrium
limacinum. The NF, an oil rich in docosahexaenoic acid (DHA), is obtained from microalgae after
enzymatic lysis. The applicant proposed to increase the use level of the NF as a food supplement, from
250 mg DHA/day (currently authorised for the general population, excluding pregnant and lactating
women) to 3 g DHA/day for adults, excluding pregnant and lactating women. S. limacinum was
attributed the qualified presumption of safety (QPS) status with the qualification ‘for production
purposes only’. Data provided by the applicant demonstrated the absence of viable cells in the NF. No
toxicological studies were performed with the NF. However, based on the available toxicological data
on oils derived from Schizochytrium sp., the QPS status of the source of the NF, the production
process, the composition of the NF and the absence of viable cells in the NF, the Panel considers there
are no concerns with regard to toxicity of the NF. The Panel considers that the data provided by the
applicant are not sufficient to conclude on the safety of the NF at the proposed uses (3 g DHA/day as
a food supplement) in adults. However, in 2012, the Panel concluded that supplemental intakes of DHA
alone up to about 1 g/day do not raise safety concerns for the general population. The
Panel concludes that the NF is safe for the use in food supplements at the maximum intake level of
1 g DHA/day for the target population (adults, excluding pregnant and lactating women).
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Schizochytrium sp. oil is authorised, in accordance with Regulation (EC) No 258/971, as a novel
food for a number of uses as listed in Commission Implementing Regulation (EU) 2017/24702
establishing the Union list of novel foods in accordance with Regulation (EU) 2015/22833. On 15 April
2019, the company Fermentalg submitted a request to the European Commission in accordance with
Article 10 of Regulation (EU) 2015/2283 for an extension of use of Schizochytrium sp. oil as a novel
food. The applicant requests to authorise use of Schizochytrium sp. oil in food supplements, excluding
food supplements for infants and young children.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on Schizochytrium sp. oil.
1.2. Information on existing evaluations and authorisations
Two existing evaluations of the NDA Panel of EFSA need to be mentioned:
• In the Scientific Opinion related to the tolerable upper intake level of eicosapentaenoic acid
(EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) (EFSA NDA Panel, 2012),
the Panel concluded that a tolerable upper intake level for DHA could not be established.
However, it was noted that supplemental intakes of EPA and DHA combined at doses up to 5
g/day, and supplemental intakes of EPA alone up to 1.8 g/day, do not raise safety concerns for
the adult population. The Panel also considered that supplemental intakes of DHA alone up to
about 1 g/day do not raise safety concerns for the general population. Limited data were
available on the effects of long-term supplementation with DHA alone at higher doses.
• In the Scientific Opinion on the extension of use for DHA- and EPA-rich algal oil from
Schizochytrium sp. as a novel food (NF) ingredient (EFSA NDA Panel, 2014), it was concluded
that the use of the NF in food supplements up to a maximum DHA and EPA content of 3 g/daily
dose for the adult population, excluding pregnant and lactating women was safe. It was
concluded that the use of the NF in food supplements up to a maximum DHA and EPA content of
3 g/daily dose for the adult population, excluding pregnant and lactating women was safe.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA requests for supplementary information. In addition,
information provided by the EFSA Panel on Biological Hazards has also been considered (EFSA BIOHAZ
Panel, 2020).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in Commission Implementing Regulation (EU) 2017/24694.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.5 As indicated in this guidance, it is
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel foods ingredients. OJ L 43, 14.2.1997, p. 1.
2 Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in
accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351,
30.12.2017, p. 72.
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1.
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
5 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva
K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M, Salminen S,
Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal
2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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the duty of the applicant to provide all of the available (proprietary, confidential and published)
scientific data, including both data in favour and not in favour of supporting the safety of the proposed
NF.
This NF application does not include a request for the protection of proprietary data.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications5 and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under




The NF which is the subject of the application is the ‘DHA-rich oil from Schizochytrium sp’. It is
produced by the microalgae Schizochytrium sp. (strain FCC-3204). With reference to article 3 of the NF
Regulation 2015/2283, the NF falls under the category 2(a)(ii): ‘food consisting of, isolated from or
produced from microorganisms, fungi or algae’. The production process involves the controlled growth
of these algae followed by extraction and refinement of the oil produced by the algae. The oil is a
mixture of triglycerides composed of polyunsaturated fatty acids (PUFA) in which DHA) represents
more than 55%. The NF is proposed to be used as food supplement at 3 g DHA/day in adults,
excluding pregnant and lactating women.
3.2. Identity of the NF
The NF under assessment in the present application is an oil rich in DHA. Common names to define
this NF are ‘DHA-rich oil from Schizochytrium sp.’ or ‘DHA-rich algal oil’. The oil produced by
Fermentalg contains more than 55% DHA.
The NF is isolated from marine microalgae belonging to the genus Schizochytrium. The taxonomic
classification of the microalgae is commonly defined as follows: Kingdom: Chromista; Phylum: Bigyra;
Class: Labyrinthula; Order: Thraustochytriida; Family: Thraustochytriaceae; Genus: Schizochytrium.
Some databases refer to the taxonomy Eukaryota, stramenopiles instead of mentioning the
Kingdom (Chromista) and the Phylum (Bigyra). Nevertheless, this is still leading to the class of
Labyrinthula (https://www.uniprot.org/taxonomy/2163902). Furthermore, the taxonomic classification
of the genus Schizochytrium has been subject to discussions in 2007 (Yokohama and Honda, 2007).
Based on genetic and phenotypic analysis, the authors proposed changes in the classification. The
genus Schizochytrium was amended and new genera such as Aurantiochytrium and Oblongichytrium
were defined. Therefore, the genus Schizochytrium can now also be referred to as Aurantiochytrium.
Upon EFSA’s request for information, the applicant specified that the strain used to produce the NF
is Schizochytrium sp. FCC-3204. This strain was obtained without use of mutagenic agents or genetic
modifications. ‘FCC 3204’ has been deposited in the Culture Collection of Algae and Protozoa (CCAP),
Scottish Marine Institute (SAMS), under the reference CCAP 4062/7.
The strain FCC-3204 is a natural variant of the strain FCC-1324, which was found by the applicant
after analysing the fatty acid (FA) profiles of a number of different isolates and retained because of its
unusually high DHA levels. The strain FCC-1324 was assessed by the Food Safety Authority of Ireland
(FSAI, 2014) and recognised as a valid source to produce the NF ‘Schizochytrium sp. oil’ which is
currently authorised on the Union list following the initial assessment by the UK Advisory Committee in
2002 (United Kingdom, 2002). Subsequently, following an assessment by the French Agency for Food,
Environmental and Occupational Health and Safety (Anses, 2018), the DHA-rich oil produced from
strain FCC-3204 was considered to be substantially equivalent to the oil from the strain FCC-1324.
Therefore, it is considered that the strain FCC-3204, subject of the current application, is a valid source
for the NF ‘Schizochytrium sp. oil’ currently authorised on the Union list.
A phylogenetic tree of the Thraustochytriceae family has been reported by the applicant. According
to the applicant, this classification is based on the comparison of sequences of the 18S small subunit
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of ribosomal DNA (18S SSU-rDNA). This analysis shows that the strain FCC-1324 (parent strain of FCC-
3204) is close to strain ATCC 20888, which is the source of the currently authorised ‘Schizochytrium
sp. oil’.
Upon EFSA’s request for information, the identity of FCC-3204 at species level was addressed by
the applicant based on the comparison of the genome sequence of FCC-1324, which is the parent
strain of FCC-3204, with the genome sequence of the type strain Aurantiochytrium limacinum ATCC
MYA-1381 (equivalent to S. limacinum ATCC MYA-1381). According to this analysis, average nucleotide
identity (ANI) between the genomes of ATCC MYA-1381 and FCC-1324 was 98.89%, and the two also
have a high degree of collinearity. These data show that the strain FCC-3204 is a member of the
species S. limacinum, which is a synonym of Aurantiochytrium limacinum (Morabito et al., 2020).
3.3. Production process
The unicellular microalgae Schizochytrium sp. (FCC-3204) are grown under controlled conditions
(time, temperature, pH and aeration) in a liquid culture medium containing the necessary nutrients.
The cultivation process starts in the laboratory. The production method and the control and verification
processes ensure that the algae used in the production are pure cultures. The water used for the
controlled growth of the microalgae and throughout the production process is food-grade and
conforms to the requirements set out by EU Directive 98/83/CE. The entire process is carried out
under inert atmosphere or vacuum conditions. Quality control evaluations are performed at each stage
of production in accordance with a HACCP system and GMP.
The microalgal biomass is lysed directly via an enzymatic hydrolysis. This lysis involves a food-grade
and non-GMO enzyme. Characteristics of this enzymatic preparation are provided by the applicant
(purity, pH range, temperature activity and temperature of inactivation). The manufacturer certifies
that the production strain of this enzyme is not present in the enzymatic preparation and that it does
not produce toxins. The enzyme was not detected in three batches of the NF. The crude oil is
recovered from the lysed biomass by centrifugation. A clarification step by filtration is performed to
remove solid matter. The crude oil is subsequently refined using standard techniques (neutralization,
decolouration and deodorisation at high temperature). At different steps of the process, EU authorised
antioxidants are added to ensure stability. The NF is finally packaged in airtight and light-proof
containers and stored at a temperature of –20°C.
The applicant provided data demonstrating that the algal strain Schizochytrium sp. (FCC-3204) does
not produce toxins and data on the absence of viable cells in the NF.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
In the application initially submitted the applicant did not provide any compositional data on the NF,
this being an application for an extension of use. However, considering that this extension of use
relates to an increase in the daily intake of the NF in food supplements to 3 g DHA, EFSA requested
the applicant to provide data on the composition of the NF. Thus, the applicant provided analytical
data for 5 independent batches of the NF (Table 1), in order to confirm that the manufacturing
process is reproducible and adequate to produce a product with the required characteristics on a
commercial scale. Information was provided on the accreditation of the laboratories that conducted
the analyses presented in the application.
The NF consists of triglycerides composed PUFA in which DHA is the predominant one, making up
together with docosapentaenoic (DPA; n-6) and palmitic acid more than 92% of the total FAs.
The proximate analytical results show that the NF is almost entirely composed of crude fat (at least
94%). The applicant provided a new analysis of 5 independent batches of the NF which reported
contents of proteins below the limit of quantification (LOQ; 0.25%).
Based on the batch-to-batch analysis, the EPA:DHA ratio of the NF ranges from 0.008:1 to 0.017:1.
The batch-to-batch analysis indicates a good reproducibility of the production process. A slight
variability of certain nutrients (vitamin E, b-carotene, iron) was observed. This was explained by the
use of food additives and processing aids in the refining step. The concentration of total sterols varied
between 9,087 and 13,375 mg/kg, which is in a similar range to that observed in different types of oils
(Yang et al., 2019).
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In terms of chemical contaminants, the concentrations of metals (< LOQs), polychlorobiphenyls
(PCBs), dioxins and polycyclic aromatic hydrocarbons found in this batch-to-batch analysis are within
the EU limits established in the respective regulations and do not present concerns from a safety point
of view. Results on the process contaminants glycidyl fatty acid esters (expressed as glycidol) and total
3-MCPD (free and FA esters) were available for four batches of the NF. Levels were below the
maximum levels (ML) for edible oils set in the EU regulation. The analyses on microbiological
contaminants in the NF are presented in Table 1. Upon EFSA’s request for information, the applicant
provided analyses on Enterobacter sakazakii, which was not detected in five batches of the NF.
The results of analyses in three batches of the NF showed that common marine biotoxins were
below the respective LOQs (diarrhetic shellfish poisoning toxins: LOQ = 20 lg/kg; pectenotoxins:
LOQ = 20 lg/kg; paralytic shellfish poisoning toxins, azaspiracids, yessotoxins, saxitoxin, okadaic acid:
LOQ = 5 lg/kg; domoic acid: LOQ = 1 mg/kg). These data confirm that the NF, produced from
Schizochytrium sp. (strain FCC-3204), is not expected to contain marine biotoxins, neither produced by
the source organism (for which a QPS status was concluded) nor from external contamination
(considering the description of the production process in Section 3.3).
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
Table 1: Batch-to-batch analysis of the NF
Parameter (unit)
Batch number




900 900 851 987 851
Fat (g/100 g) > 99.22 > 99.22 > 93.78 > 99.4 > 93.78
Proteins
(g/100 g)(a)
< 0.5(d) < 0.5(d) < 0.5(d) 0.6 < 0.5(d)
Carbohydrates
(g/100 g)
< 0.1 < 0.1 < 0.1 < 0.1 < 0.1
Crude ash
(g/100 g)
< 0.25 < 0.25 < 0.25 < 0.25 < 0.25
Salt (g/100 g) 0.0135  0.0131 0.0390  0.0136 0.0163  0.0131 < 0.01 0.0250  0.0132
Sodium (g/100 g) 0.005  0.005 0.016  0.005 0.007  0.005 < 0.005 0.011  0.005
Physico-chemical parameters
p-Anisidine value 6.1 2.0 7.3 1.6 5.6
Moisture and
volatiles (%)
< 0.1(e) < 0.1(e) < 0.1(e) < 0.1(e) < 0.1(e)
Unsaponifiable
matter (%)
1.5 1.2 1.4 1.4 1.1
Acid value (mg
KOH/g)
0.4 0.2 0.2 0.4 0.5
Peroxide value
(meq/kg)
1.7 0.5 1.1 2.1 1.1
Density (kg/L) NA 0.94700 0.9452  0.0008 0.9493  0.0008 0.9452  0.0008
Relative density NA 0.9487 0.9469  0.0008 0.9480  0.0008 0.9469  0.0008
Tocopherols (mg/100 g)
a-Tocopherol 26.2 26.2 13.9 26.8 14.1
b-Tocopherol 4.06 4.01 2.05 3.12 2.13
d-Tocopherol 85.8 74.2 39.3 69.5 38.7
c-Tocopherol 195 171 87.5 162 86.3




NA < 5 49.1  13.7 < 5 < 5
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Parameter (unit)
Batch number




NA < 2 < 2 < 2 < 2
Astaxanthin
(mg/100 g)
NA < 2 < 2 < 2 < 2
Canthaxanthin
(mg/100 g)
NA < 2 < 2 < 2 < 2
Fatty acids (% total FA)
Myristic – 14:0 0.4 0.4 0.6 0.4 0.6
Palmitic – 16:0 13.9 13.3 15.8 12.8 15.8
Margaric – 17:0 NA 0.1 NA NA NA
Heptadecenoic –
17:1
NA 0.2 NA NA NA
Hexadecenoic –
16:1 TOTAL
0.1 0.1 0.1 0.1 0.1
Stearic – 18:0 0.7 0.6 0.7 0.6 0.7
Oleic – 18:1(n-9) 0.3 0.2 0.1 0.1 0.1
cis-Vaccenic - 18:1
(n-7)
0.1 0.1 0.1 0.1 0.1
Linoleic – 18:2(n-
6)
0.5 0.3 NA 0.1 NA
c-Linolenic – 18:3
(n-6)
0.2 0.2 0.1 0.2 0.1
a-Linolenic - 18(n-
3)
0.4 0.4 0.2 0.4 0.2
Stearidonic -18:4
(n-3)
0.5 0.5 0.3 0.5 0.3
Arachidic – 20:0 0.1 0.1 0.1 0.1 0.1
Homo-c-linolenic –
20:3(n-6)
0.2 0.2 0.2 0.2 0.2
Arachidonic – 20:4
(n-6)
0.4 0.4 0.4 NA 0.4
Eicosatetraenoic –
20:4(n-3)
0.6 0.6 0.6 0.6 0.6
Eicosapentaenoic
(EPA) – 20:5(n-3)
1.1 0.8 0.5 0.8 0.5
Behenic – 22:0 0.1 0.1 0.1 0.1 0.1
Docosapentaenoic
(DPA)– 22:5(n-6)
13.4 13.3 13.8 13.4 13.9
Docosapentaenoic
(DPA)– 22:5(n-3)
0.3 0.3 0.2 0.2 0.2
Docosahexaenoic
(DHA) – 22:6(n-3)
65.1 66.9 64.2 67.7 64.3
Others unidentified 1.6 0.9 1.9 1.6 1.7




13,375 9,087 NA NA 9,581
Metals (mg/kg)
Mercury < 0.005(d) < 0.005(d) < 0.005(d) < 0.005(d) < 0.005(d)
Cadmium < 0.005(d) < 0.005(d) < 0.005(d) < 0.005(d) < 0.005(d)
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Parameter (unit)
Batch number
0403019 0413022 0418028 0419022 0419028
Total arsenic < 0.01(d) < 0.01(d) < 0.01(d) < 0.01(d) 0.01 (0.003)
Lead < 0.01(d) < 0.01(d) < 0.01(d) < 0.01(d) < 0.01(d)
Copper < 0.05(d) < 0.05(d) < 0.05(d) < 0.05(d) < 0.05(d)





< 1,000 < 1,000 < 1,000 < 1,000 < 1,000
Moulds < 10 < 10 < 10 < 10 < 10
Yeast < 10 < 10 < 10 < 10 < 10
Coliform 30°C < 1 < 1 < 1 < 1 < 1
Thermotolerant
coliforms




< 1 Absence/10 g Absence/10 g Absence/10 g Absence/10 g
Coagulase-positive
staphylococci
< 10(b) Absence/1 g Absence/1 g Absence/1 g Absence/1 g
Sulfite-reducing
anaerobic bacteria
< 1 < 1 < 1 < 1 < 1
Clostridium
perfringens
< 1 < 1 < 1 < 1 < 1
Bacillus cereus < 10 < 10 < 10 < 10 < 10
Salmonella Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Listeria
monocytogenes
Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Enterobacteria at
30°C
< 10 < 10 < 10 < 10 < 10
PCB and dioxins
Sum of dioxin and
furans (PCDD/Fs
TEQ) (pg/g)(c)
NA 0.338 0.337 0.172 0.340
PCB (dioxin like –
TEQ) (pg/g)(c)




NA 0.543  0.136 0.541  0.135 0.275  0.069 0.546  0.137
PCB (total 6 ndl-
PCB) (ng/g)(c)
NA 1.97 1.96 0.992 1.98
Polycyclic aromatic hydrocarbons (lg/kg)
Benzo(a)pyrene NA < 0.5 < 0.5 < 0.5 < 0.5
Benzo(a)
anthracene
NA < 0.5 < 0.5 < 0.5 < 0.5
Chrysene NA 0.8  0.4 < 0.5 < 0.5 < 0.5
Benzo(b)-
fluoranthene
NA 0.7  0.5 < 0.5 < 0.5 < 0.5





NA Not calculable(f) Not calculable(f) Not calculable(f) 22 ( 11)
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3.4.1. Stability
In the application initially submitted the applicant did not provide any data on the stability of the
NF.
Upon EFSA’s request for information, the applicant indicated that the NF is to be stored at a
temperature at or below –15°C (frozen conditions), away from light, heat and oxygen.
Upon EFSA’s request for information, the applicant provided stability studies on four batches of the
NF under the proposed storage conditions (–15°C) as well as at 4°C, 25°C/60% RH and 40°C/75% RH.
The content of DHA and markers of oxidation (peroxide value, p-anisidine value, TOTOX value and
acid value) were analysed regularly during the studies. The markers of oxidation tested were within
the limits set in the specifications (peroxide value < 5.0 meqO2/kg and acid value < 0.5 mg KOH/g) in
the NF batches tested at –15°C and 25°C up to 55 weeks (n = 2) and up to 2 years (n = 2), as well as
in the NF batches (n = 2) tested at 4°C up to 45 weeks and (n = 3) at 40°C up to 24 weeks. The DHA
content remained above 55% (w/w) in all NF batches tested up to the end of the duration of these
studies. The NF samples were also tested for p-anisidine value and TOTOX value, which remained
within the values indicated by the applicant (p-anisidine value < 20 and TOTOX value < 26) up to the
end of the stability tests. The Panel notes that the p-anisidine value, which indicates the oxidative
stability of the NF, was below 10 throughout the stability tests.
Based on the stability studies provided, the applicant proposed a shelf life for the NF of 2 years
from the date of manufacture, to be stored at a temperature at or below –15°C (frozen conditions),
away from light, heat and oxygen.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF during the proposed shelf life of 2 years.
3.5. Specifications
As the NF ‘Schizochytrium sp. oil’ is already authorised on the EU market, specifications for this NF
are currently presented in the Union list. The Panel verified whether the NF under assessment
complies with these specifications and subsequently assessed the need to define further specifications
for the NF under assessment.
Current specifications of the NF (Union list)
Parameters and corresponding values of the current specifications for ‘Schizochytrium sp. oil’ are
reported in Table 2. It is noted that the NF currently authorised is not strain specific. Furthermore, the
microalgae that is the source of the NF under assessment is currently used as a source for the
authorised NF ‘Schizochytrium sp. oil’ (see Section 3.2). Therefore, the NF under assessment shall
comply with the specifications currently defined for ‘Schizochytrium sp. oil’. A comparison with the data
from the batch-to-batch analysis of the present NF is presented in Table 2.
According to the data submitted in the present dossier, the NF produced by the applicant complies
with the current specifications for ‘Schizochytrium sp. oil’.
Parameter (unit)
Batch number





NA < 100(d) < 100(d) < 100(d) 150 ( 70)
LOD: limit of detection; NA: not analysed; ND: not detected; LOQ: limit of quantification; MCPD: monochloro-propanol-1,2-diol;
PCB: polychlorobiphenyl; dl-PCB: dioxin-like PCB; ndl-PCB: non dioxin-like PCB; PCDD/Fs: polychlorinated dibenzo-p-dioxins and
dibenzofurans; TEQ: toxicological equivalency.
(a): The applicant provided an additional analysis on total nitrogen in 5 independent batches of the NF which contained proteins
below LOQ (0.25%).
(b): A different method was used to analyse this batch as compared to the other batches.
(c): Upper bound results. Upper bound means levels below LOQ (for each congener) are set equal to the LOQ.
(d): LOQ.
(e): LOD.
(f): Glycidyl fatty acid esters were calculated from two parameters ‘total 3-MCPD and glycidyl fatty acid esters’ and ‘3-MCPD
total’. Since both ‘total 3-MCPD and glycidyl fatty acid esters’ and ‘3-MCPD total’ were below LOQ (100 lg/kg) it was not
possible to calculate ‘glycidyl fatty acid esters’.
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The maximum values observed in the batch-to-batch analysis for the acid value, peroxide value,
moisture and volatiles, unsaponifiable and trans-FAs are below the limits defined in the specifications
(see Table 2). The results of the storage stability studies indicated that the specifications are expected
to be met when the NF is stored under the proposed conditions of storage (see Section 3.4.1).
The NF under assessment complies with the specifications for ‘Schizochytrium sp. oil’ that is already
authorised on the EU market.
Discussion on additional specifications for the uses assessed in the present dossier
The applicant used a strain of Schizochytrium sp. (strain FCC-3204) in the production of the NF and
this strain impacts on the FA profile of the NF. Notably, concentrations of DHA range between 64.2%
and 67.7% of the FA content, while the minimum required by the specifications is 32% (w/w).
Therefore, the applicant proposed to amend the current specifications of the Union list to consider this
particularity of the NF. The Panel considers that amending the specification to modify the minimum
concentrations of DHA (i.e. > 55% instead of 32%) is not necessary from a safety point of view.
The applicant proposed to add the parameter ‘free fatty acids’ (≤ 0.3%). The Panel notes that the
parameter ‘acid value’, which is included in the currently authorised specifications, correlates with the
presence of free FAs. Thus, the Panel considers that it is not necessary to amend the currently
authorised specifications of the NF in this respect.
The Panel notes that the p-anisidine value, which allows monitoring the secondary oxidation of oils,
has not been considered so far on the Union list for Schizochytrium oils. However, secondary oxidation
products (such as a,b-unsaturated carbonyl compounds, malonaldehyde) may be of safety concern
(Vieira et al., 2017; Kanner, 2007). Therefore, the Panel proposes to add the p-anisidine value in the
specifications for Schizochytrium sp. oils. Considering the European Pharmacopoeia values defined for
cod liver and salmon oils (2015) and the compositional data, a maximum limit of 10 could be used for
the p-anisidine value in Schizochytrium oils.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The source of the NF is a microalgae belonging to the genus Schizochytrium (see full description in
Section 3.2). This genus has been used as a source of DHA-rich oils since 2003, year of the first
authorisation of the NF DHA-rich oil from Schizochytrium sp. (Commission Decision 2003/427/EC6). The
first assessment of DHA-rich oil from Schizochytrium sp. involved the strain ATCC 2088 (United Kingdom,
2002). However, several other strains have been recognised as valid sources for this NF since 2003.
Table 2: Specifications of the NF (as currently reported in the Union list) and comparison with





NF under assessment (based




≤ 0.5 0.5 (max) Not reported on the UL
Peroxide value
(PV) (meq/kg)
≤ 5.0 2.1 (max) Not reported on the UL
Moisture and
volatile (%)
≤ 0.05 < 0.1 (LOD) Not reported on the UL
Unsaponifiables
(%)
≤ 4.5 1.5 (max) Not reported on the UL
Trans-fatty acids
(%)
≤ 1.0 < 0.05(a) Not reported on the UL
DHA content (%) ≥ 32.0 64.2–67.7(a) Not reported on the UL
DHA: docosahexaenoic acid; LOD: Limit of detection; UL: Union list.
(a): % of fatty acids.
6 Commission Decision 2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in DHA
(docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of
the European Parliament and of the Council; OJ L 144, 16.6.2003, p. 13–14.
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Following two substantial equivalence assessments (FSAI, 2014 and Anses, 2018), two other strains
(FCC-1324 and FCC-3204, respectively) were recognised as valid sources to produce DHA-rich oils
equivalent to the original NF. On the current Union list, the DHA-rich oils produced from these strains
are commonly referred to as ‘Schizochytrium sp. oil’ under Regulation (EU) 2014/4637.
3.6.2. History of use of the NF
The application under assessment is an extension of use for the first authorised DHA-rich oil,
referred to as generic Schizochytrium sp. oil. This NF has been authorised since 2003 by means of
Commission Decision 2003/427/EC6. It has been subject to several extensions of use which were
reported in Commission Decision 2009/778/EC8, Commission Implementing Decision 2014/463/EU9 and
Commission Implementing Regulation 2019/10910. The NF Schizochytrium sp. oil is currently
authorized as a food supplement (250 mg DHA/day for the general population; 450 mg DHA/day for
pregnant and lactating women) and as a food ingredient in a wide range of food categories.
A food supplement with the maximum daily intake of 3,000 mg DHA and EPA combined is
authorised but is strictly limited to the ‘Schizochitrium sp. oil rich in DHA and EPA’.
3.6.3. Safety assessment for DHA
Upon request of the European Commission, the safety of omega-3 long-chain PUFA (DHA, EPA and
DPA), consumed either individually or in combination, was assessed by the NDA Panel in 2012 (EFSA
NDA Panel, 2012). The Panel concluded that available data were insufficient to establish a tolerable
upper intake level (UL) for EPA, DHA and DPA (individually or combined) for any population group. In
the absence of a UL, the Panel provided advice on a daily supplemental intake of n-3 LCPUFAs (i.e.
intake of n-3 LCPUFAs taken as food supplement, either individually or combined) which does not give
rise to concerns about adverse health effects.
In 2012, based on the available evidence, the Panel concluded that ‘supplemental intakes of DHA
alone up to about 1 g/day do not raise safety concerns for the general population’. The safety
assessment was based on few studies conducted with supplements containing DHA (typically isolated
from microalgae). Regarding the combination of EPA and DHA, the Panel concluded ‘supplemental
intakes of EPA and DHA combined at doses up to 5 g/day do not raise safety concerns for the adult
population’. In most human intervention studies considered, fish oils were used as a source of
combined EPA and DHA (EFSA NDA Panel, 2012).
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
Upon EFSA’s request for clarifications, the applicant indicated that the target population is adults
(i.e. individuals aged 18 years and above), excluding pregnant and lactating women.
3.7.2. Proposed uses and use levels
The applicant intends to increase the use level of the NF as a food supplement, from 250 mg DHA/
day (currently authorised for the general population, excluding pregnant and lactating women) to 3 g
DHA/day for adults, excluding pregnant and lactating women.
7 Regulation (EU) 2014/463: Commission Implementing Decision of 14 July 2014 on authorising the placing on the market of oil
from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC. OJ L 209, 16.7.2014, p. 55–58.
8 Commission Decision 2009/778/EC: Commission Decision of 22 October 2009 concerning the extension of uses of algal oil
from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council; OJ L 278, 23.10.2009, p. 56–57.
9 Commission Implementing Decision 2014/463/EU: Commission Implementing Decision of 14 July 2014 on authorising the
placing on the market of oil from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC; OJ L 209,
16.7.2014, p. 55–58.
10 Commission Implementing Regulation (EU) 2019/109 of 24 January 2019 authorising an extension of use of Schizochytrium
sp. oil as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending
Commission Implementing Regulation (EU) 2017/2470; OJ L 23, 25.1.2019, p. 7–10.
Safety of oil from Schizochytrium limacinum (strain FCC-3204) – food supplements
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2021;19(1):6345
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant did not submit specific ADME data for the NF. Digestion, absorption and metabolism
of DHA has been extensively documented in the EFSA Scientific Opinion on Tolerable Upper Intake
Level of EPA, DHA and DPA (EFSA NDA Panel, 2012).
3.9. Nutritional information
The nutritional content of the NF is provided by the batch-to-batch analysis. The NF mainly consists
of fats in the form of triglycerides. trans-FAs were not detected, and based on the acid value, free FAs
are not expected to be of concern. The FA profile indicates that DHA is the predominant compound in
the NF.
The analysis of the composition shows the presence of other nutrients such as sodium, vitamin E,
b-carotene. However, given that the proposed maximum daily amount of the NF (3 g DHA which
corresponds to 5.5 g of NF), the presence of those nutrients is not expected to be of health concern.
The Panel considers that taking into account the composition of the NF and the proposed
conditions of use, consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
3.10.1. Qualified presumption of safety (QPS)
The available evidence indicates that the source organism (Schizochytrium sp., strain FCC-3204)
belongs to the species S. limacinum. In 2020, S. limacinum was assessed by the EFSA Panel on
Biological Hazards (BIOHAZ) for its suitability to be added to the list of QPS-recommended biological
agents intentionally added to food or feed. In the opinion of the BIOHAZ Panel, S. limacinum was
identified as a synonym of Aurantiochytrium limacinum. The BIOHAZ Panel considered the identity, the
body of knowledge and potential safety concerns of this microorganism. The literature searches
performed did not provide any evidence for a safety concern for human or animal health for any use
of S. limacinum. The BIOHAZ Panel concluded that S. limacinum is recommended for the QPS list with
the qualification ‘for production purposes only’ (EFSA BIOHAZ Panel, 2020).
3.10.2. Absence of marine biotoxins
The absence of marine biotoxins was demonstrated in the assessment of the composition of the NF
(see Section 3.4). The Panel investigated whether the LOQs used in the reported analysis of the
common marine biotoxins were sufficiently low compared to the acute reference dose (ARfD) of the
respective biotoxins (EFSA CONTAM Panel, 2009). It was found that the theoretical intakes resulting
from the occurrence of marine biotoxins at their respective LOQs remained well below the respective
ARfD of the corresponding biotoxins. It is concluded that the reported LOQs are sufficiently low to
ensure consumer safety.
3.10.3. Toxicity of DHA-oils derived from Schizochytrium sp.
No toxicity studies that were conducted with the NF under assessment (DHA-rich oil produced from
strain FCC-3204 of Schizochytrium sp.) have been provided by the applicant.
However, the toxicity of DHA-rich algal oils produced from different strains of Schizochytrium sp.
has been extensively investigated over the last decades. Several guideline compliant studies, including
bacterial reverse mutation tests, in vitro chromosomal aberration tests, in vivo mammalian cell
micronucleus tests, subchronic toxicity studies with rats, and developmental and reproductive toxicity
studies with rats, were performed with various forms of DHA algal oils from Schizochytrium sp. Most of
these studies were assessed and used to conclude on the safety of NFs evaluated in former
authorisation frameworks. Notably two studies performed with DHA-oil produced from strain ATCC
PTA-9695 (Fedorova-Dahms et al., 2011 and an unpublished study) were performed to support the
authorisation of the NF Schizochytrium sp. (ATCC PTA-9695) in infant and follow-on formula. These
studies have been assessed by the UK competent authority in 2014 (United Kingdom, 2014). Similarly,
two other studies performed with DHA-oil produced from strain T18 (Schmitt et al., 2012a,b) have also
been considered by the UK competent authority in support of the authorisation of the NF
Schizochytrium sp. (T18) in infant and follow-on formula in 2017 (United Kingdom, 2017). In addition,
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two other studies (Lewis et al., 2016; Falk et al., 2017), performed with DHA-oils from unspecified
strains of Schizochytrium sp., have been considered in the assessment carried out by Anses (2018).
In all previous assessments, the competent authorities concluded that there were no concerns with
regard to genotoxicity and subchronic toxicity of the tested materials. Further studies found in the
literature indicate the same outcome for a diversity of DHA-oils produced from other strains of
Schizochytrium sp. which have a longer history of use (Hammond et al., 2001a, 2001b, 2002; Blum
et al., 2007; Kroes et al., 2003; Abril et al., 2003).
3.10.4. Summary
Even though toxicological tests were not conducted with the NF that is assessed in the present
opinion, the Panel considers that, given the results on toxicity in studies performed with various forms
of DHA-rich oils derived from Schizochytrium sp., given the QPS status of the source of the NF, and
considering data on the production process and on the composition of the NF and the absence of
viable cells, there are no concerns with regard to toxicity of the NF.
3.10.5. Human data
Upon EFSA’s request, the applicant provided human studies to support the safety of DHA
supplementation for the extension of use of the NF to 3 g DHA/day.
For the assessment of this NF application, the Panel referred to the 2012 EFSA opinion, which
concluded that supplemental intakes of DHA alone up to about 1 g/day do not raise safety concerns
for the general population. That opinion also concluded that supplemental intakes of EPA and DHA
combined at doses up to 5 g/day do not raise safety concerns for the general population. It was noted
that in the majority of the human studies considered, fish oils, which also contained DPA in generally
unknown (but relatively low) amounts, were the source of EPA and DHA. A typical fish oil supplement
provides EPA and DHA in a ratio of 3:2, but 2:1 and higher ratios are also commonly found in fish oils
(Harris, 2004; NIH, 2019).
The Panel notes that the EPA:DHA ratio of the NF ranges from 0.008:1 to 0.017:1 based on the
batch analyses and hence deviates significantly from the EPA:DHA ratio reported for fish oils. In this
context, the applicant claims a conversion factor of DHA into EPA of 3–14% based on studies showing
an increase of EPA in serum (Conquer and Holub, 1997, 1998) and in serum and red blood cells (RBC)
following ingestion of DHA supplements (Schuchardt et al., 2016). However, the results from a recent
study using compound-specific isotope analysis showed that the increase in plasma EPA following DHA
supplementation in humans does not occur via retroconversion, but instead from a slowed metabolism
and/or accumulation of plasma EPA (Metherel et al., 2019).
The Panel notes that the data gaps and safety concerns identified in the 2012 opinion for
supplementation of DHA (alone) were: bleeding complications, bleeding time, glucose homeostasis,
LDL-cholesterol and immune function. For the endpoints ‘platelet function’ and ‘lipid peroxidation’, the
Panel could identify a dose of up to 4–5 g/day of DHA alone which was not considered to have
adverse health effects.
Eight clinical trials provided by the applicant were carried out with supplementation of DHA at
doses equal or above 3 g/day. Results from several of these clinical trials have been published in
different publications reporting on various parameters or outcomes. The Panel notes that no
conclusions can be drawn from the study by Rontoyanni et al. (2012) which investigated the effect of
single consumption of a meal enriched with DHA.
Details of these clinical trials are summarised in Table 3. The Panel notes that only one clinical trial
was conducted with DHA oil from the microalgae Schizochytrium sp. The clinical trials reported on
effects of supplemental intake of DHA on blood lipid parameters, glucose homeostasis, immune
function and/or adverse events. None of these studies addressed possible adverse effects of DHA
supplementation on bleeding time or bleeding complications.
Blood lipids
Four clinical trials reported on LDL-cholesterol or other blood lipid parameters in relation to DHA
supplementation (≥ 3 g/day) (Kelley et al., 2007, 2008; Hughbanks-Wheaton et al., 2014; Domingo
et al., 2018a; Klingel et al., 2019).
Supplementation with 3 g/day of DHA in a trial in hyperlipidemic men showed a statistically
significant difference in effect on LDL cholesterol (15% higher in the DHA group – Kelley et al., 2007)
and on fasting remnant like particle cholesterol (21% lower in the DHA group – Kelley et al., 2008)
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during a 90 day intervention. In a study in HIV-infected men supplemented with 4 g/day of DHA for 48
weeks (Domingo et al., 2018a),no statistically significant differences in blood parameter changes over
time were observed between the DHA and the control groups, except for a reduction in triglyceride
levels which were more pronounced in the DHA group. In two trials, there were limited and no
statistically significant differences in changes in LDL-, HDL- or total cholesterol levels between the
group supplemented with DHA and the control group (Hughbanks-Wheaton et al., 2014; Klingel et al.,
2019). The Panel notes that in the trial by Hughbanks-Wheaton et al. (2014), only 30% of the study
population are above 18 years and correspond to the target population of the NF (i.e. adults).
The Panel notes that the trials tested DHA oils other than the NF, that only one trial was carried out
in healthy normolipidemic women and men (Klingel et al., 2019), while the remaining three trials
(Kelley et al., 2007, 2008; Hughbanks-Wheaton et al., 2014; Domingo et al., 2018a) were conducted in
populations not or only partially corresponding to the target population for the NF (i.e. adults).
The Panel considers that based on the studies provided no conclusions can be drawn on the safety
of the NF at the proposed use of 3 g DHA/day on effects on LDL cholesterol or other blood lipids in
the general adult population.
Glucose homeostasis
Four clinical trials reported on parameters of glucose homeostasis in relation to DHA
supplementation (≥ 3 g/day) (Kelley et al., 2012; Hughbanks-Wheaton et al., 2014; Domingo et al.,
2018a; Klingel et al., 2019).
In the trial by Domingo et al. (2018a), fasting glucose, insulin, C-peptide, homeostasis model
assessment of insulin resistance (HOMA-IR) and glycosylated haemoglobin levels were not statistically
significantly different (as compared to baseline or between the DHA and control groups) throughout
the study. The trial by Hughbanks-Wheaton et al. (2014) reported no statistically significant differences
in changes from baseline in fasting blood glucose concentrations between the group supplemented
with DHA and the control group. In the trial by Klingel et al. (2019), the effect of DHA
supplementation on fasting blood glucose concentrations was not statistically significantly different as
compared to control. In the trial by Kelley et al. (2012), DHA supplementation statistically significantly
increased fasting plasma glucose concentration as compared to baseline, but did not significantly alter
other indices of insulin resistance (fasting or postprandial insulin concentrations, postprandial glucose
concentrations, HOMA-IR). Changes in the above glucose and insulin parameters were not statistically
significantly different between the DHA and control groups.
The Panel notes that the studies provided do not show any adverse effects of DHA supplementation
of 3 g/day on the investigated markers of glucose homeostasis. However, the Panel notes that
measurements of blood glucose alone (as in the trials by Klingel et al., 2019 and Hughbanks-Wheaton
et al., 2014) are not sufficient to draw overall conclusions on possible effects of DHA supplementation
on glucose homeostasis. The Panel also notes that glucose and insulin measurements were not the
primary outcomes in the trial by Kelley et al. (2012). Lastly, the Panel notes the limitations of these
trials regarding the study populations (see Table 3) that did not correspond or partially corresponded
to the target population of the NF (i.e. adults).
The Panel considers that based on the evidence provided no conclusions can be drawn on the
safety of the NF at the proposed use of 3 g DHA/day on possible effects on glucose homeostasis in the
general adult population.
Immune function
Three clinical trials reported on markers of inflammation in relation to DHA supplementation (≥ 3 g/day)
(Kelley et al., 2009; Domingo et al., 2018b; Pastor et al., 2019).
The trial by Pastor et al. (2019) was conducted in patients with cystic fibrosis. The Panel considers
that no conclusions can be drawn from this study on the effect of DHA supplementation on markers of
inflammation.
In a trial in hypertriglyceridemic men (Kelley et al., 2009), a 3 g/day DHA supplementation during a
90 days intervention showed statistically significant changes over time in the DHA group (showing
decreases in circulating neutrophils (by 10.5%), white blood cells (by 6%), C-reactive protein (by
15%), interleukin-6 (by 23%) and granulocyte monocyte-colony stimulating factor (by 21%) and an
increase (by 7%) in the concentration of anti-inflammatory matrix metalloproteinase-2. However, no
statistically significant differences in changes between the DHA group and the control group were
reported. In the trial by Domingo et al. (2018b) in HIV patients, there were no statistically significant
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differences in changes in the inflammatory parameters investigated between the DHA and the control
groups (except for monocyte chemoattractant-protein 1).
The Panel notes that the studies provided do not indicate adverse effects of DHA supplementation
of 3 g/day on the investigated markers of inflammation. However, the Panel notes the limitations of
these studies regarding the study populations that did not correspond or partially corresponded to the
target population of the NF and the limited data on immune functionality. The Panel considers that
based on the evidence provided no conclusions can be drawn on the safety of the NF at the proposed
use of 3 g DHA/day on possible effects on immune function in the general adult population.
Adverse events
Six clinical trials reported on adverse events in relation to DHA supplementation (≥ 3 g/day) (Kelley
et al., 2012; Hoffman et al., 2014; Hughbanks-Wheaton et al., 2014; Oliver et al., 2016; Domingo
et al., 2018a; Lee et al., 2019; Metherel et al., 2019).
In the trial reported by Hoffman et al. (2014) and Hughbanks-Wheaton et al. (2014), 51
participants (out of the 78 enrolled) had no related or possibly related treatment emergent adverse
events (TEAEs). Twenty-seven participants reported 42 related or possibly related TEAEs (22 in the
DHA group and 20 in the control group). Gastrointestinal (GI) events were the main reported events (n =
6 in DHA and n = 4 in the control group). One participant in the DHA group had recurrent GI symptoms
such as diarrhoea, flatulence and eructation. Only one blood chemistry TEAE event was observed in the
DHA group (elevated serum glutamate pyruvate transaminase), whereas none was observed in the
control group. No severe TEAEs requiring hospitalization were reported during the 4-year duration of this
trial. In the trial by Kelley et al. (2012), two subjects in the DHA group did not complete the study owing
to GI symptoms (feeling of gas/bloating). In the study by Oliver et al. (2016), side effects of
supplementation with DHA oil, obtained from microalga Schizochytrium sp., were reported by participants
(i.e. transient GI distress). These effects were reported only once over the duration of the study. In the
trial by Domingo et al. (2018a), the occurrence of TEAEs was not more frequent in the DHA group than in
the control group. GI disorders such as fishy smell belching, nausea, and bloating were most common
adverse events. They did not lead to treatment discontinuation except for three participants in the DHA
group and one participant in the control group. Laboratory parameters including transaminases did not
show significant variation in either arm. In the study by Metherel et al. (2019), none of the participants
reported any adverse events of the intervention with either DHA or EPA. In the study by Lee et al. (2019),
DHA and olive oil (control) evoked similar responses in resting blood pressure, but only DHA increased
peripheral vasoconstrictor outflow. In this study, none of the participants reported any adverse effects
associated with the interventions.
The Panel notes that the studies provided do not indicate any severe adverse events associated with
DHA supplementation up to 6 g/day over several weeks up to 1 year and in one study up to 4 years.
Reported adverse events comprise GI effects such as bloating, nausea, unpleasant breath or diarrhoea.
The clinical relevance of the elevated peripheral vasoconstrictor outflow observed in one study is unclear.
Overall considerations
In summary, the Panel notes that the study populations in several studies did not correspond to the
target population (Kelley et al., 2007, 2008, 2009, 2012; Hoffman et al., 2014; Hughbanks-Wheaton et al.,
2014; Domingo et al., 2018a,b), that only one study was carried out with DHA-rich oil from Schizochytrium
sp. (Oliver et al., 2016) and that only two studies reported on blood chemistry-related TEAEs (Hughbanks-
Wheaton et al., 2014; Domingo et al., 2018a). The Panel notes that the parameters of interest for the
assessment of this NF were not primary outcomes in the studies provided (except for Kelley et al., 2007)
and therefore these studies were not originally designed and powered for the purpose of drawing
conclusions on these parameters. No new studies were provided with respect to possible adverse effects of
DHA supplementation at the proposed use of the NF on bleeding time or bleeding complications.
Overall, the Panel considers that the available evidence from the studies provided by the applicant is
not sufficient to overcome concerns expressed in the 2012 opinion regarding possible adverse effects of
DHA supplementation at 3 g/day on LDL-cholesterol concentrations, glucose homeostasis, immune
function or bleeding complications. Thus, the Panel considers that the data provided by the applicant
are not sufficient to conclude on the safety of the NF at the proposed uses (3 g DHA/day) in adults.
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Table 3: Summary of the human intervention studies provided by the applicant which investigated
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3.11. Allergenicity
Upon EFSA’s request for information, the applicant provided a new analysis of 5 batches of the NF,
which indicated that proteins were below the LOQ (0.25%). The Panel considers that the NF is unlikely
to trigger adverse allergic reactions in the general population or subgroups thereof under the proposed
conditions of use.
4. Discussion
The NF, which is the subject of the application, is a DHA-rich oil derived from Schizochytrium sp.
(FCC-3204). The available evidence indicates that the source organism (Schizochytrium sp., strain FCC-
3204) belongs to the species S. limacinum. The source organism which is assessed in this application
is S. limacinum (FCC-3204) and not the generic Schizochytrium sp. The Panel considers that the
information provided on the composition of the NF is sufficient and does not raise safety concerns.
In 2020, S. limacinum was assessed by the EFSA BIOHAZ Panel and attributed the QPS status with
the qualification ‘for production purposes’, which implies the absence of viable Schizochytrium cells in
the final product. Data provided by the applicant demonstrated the absence of the viable cells in the
NF. The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
The applicant intends to increase the use level of the NF as a food supplement, from 250 mg DHA/
day (currently authorised for the general population, excluding pregnant and lactating women) to 3 g
DHA/day for adults, excluding pregnant and lactating women.
Toxicological tests with the NF were not performed. However, based on the available toxicological
data on various forms of DHA-oils derived from Schizochytrium sp., the QPS status of the source of the
NF, the production process, the composition of the NF and the absence of viable cells in the NF, the
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The safety concerns identified in the 2012 opinion for supplementation of DHA were bleeding
complications, bleeding time, glucose homeostasis, LDL-cholesterol and immune function. The
Panel considers that the evidence in human intervention studies provided by the applicant to support
the extension of use to 3 g DHA/day in adults (excluding pregnant and lactating women) is not
sufficient to overcome these concerns. Therefore, the Panel considers that the data provided by the
applicant are not sufficient to conclude on the safety of the NF at the proposed uses (3 g DHA/day) in
adults. However, the Panel notes that in the 2012 opinion it was concluded that supplemental intakes
of DHA alone up to about 1 g/day did not raise safety concerns for the general population.
5. Conclusions
The Panel concludes that the NF, i.e. Schizochytrium sp. oil (produced from the strain FCC-3204
belonging to species S. limacinum), is safe for the use in food supplements at the maximum intake
level of 1 g DHA/day for the target population proposed by the applicant (adults, excluding pregnant
and lactating women).
6. Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the request
for a scientific opinion on the safety of Schizochytrium sp. oil as a novel food Ref. Ares(2019)
4415804, dated 10 July 2019.
2) On 10/07/2019, a valid application on Schizochytrium sp. oil, which was submitted by
Fermentalg, was made available to EFSA by the European Commission through the
Commission e-submission portal (NF 2019/1046) and the scientific evaluation procedure was
initiated.
3) On 20/12/2019, EFSA requested the applicant to provide additional information to accompany
the application and the scientific evaluation was suspended.
4) On 03/09/2020, additional information was provided by the applicant and the scientific
evaluation was restarted.
5) During its meeting on 24 November 2020, the NDA Panel, having evaluated the data, adopted
a scientific opinion on the safety of oil from Schizochytrium limacinum (strain FCC-3204) for
use in food supplements as a NF pursuant to Regulation (EU) 2015/2283.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
AI adequate intake
ANI average nucleotide identity
ARfD acute reference dose
ATCC American Type Culture Collection
BIOHAZ Panel on Biohazards
bw body weight
CCAP Culture Collection of Algae and Protozoa
CFU colony forming unit
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FA fatty acids
GI gastrointestinal
GMO genetically modified organism
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Points
HDL high-density lipoprotein
HIV human immunodeficiency virus




LOD limit of detection
LOQ limit of quantification
MCPD monochloro-propanol-1,2-diol
ML maximum level
NDA Panel on Nutrition, Novel Foods and Food Allergens
NF novel food
PCB polychlorobiphenyles
PUFA polyunsaturated fatty acids
PV peroxide value
QPS qualified presumption of safety
RBC red blood cells
rDNA ribosomal DNA
RH relative humidity
SAMS Scottish Marine Institute
TEAE treatment emergent adverse events
TEQ toxicological equivalency
TG triglyceride
UL tolerable upper level of intake
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